SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that researchers at the National Institute of Virology (NIV) in India have documented that the Aethlon Hemopurifier® is highly efficient in capturing infectious dengue virus. In preliminary studies, the Aethlon Hemopurifier® removed 99.6% of live dengue virus from fluids in 30 minutes. The NIV is the Government of India’s leading infectious disease research center and a collaborating laboratory of the World Health Organization (WHO). “The data resulting from the NIV study exceeds expectations,” stated Aethlon Chairman and CEO, James A. Joyce. “We will continue to initiate programs that support the commercialization of the Hemopurifier® as a potential treatment for dengue and other viral threats resistant to drug and vaccine therapy.”
